Designed around a documentation check, not a brand story.
API manufacturer site design puts DMF and CEP status ahead of brand narrative, because that documentation is what a formulator actually checks first when shortlisting a supplier.
Manufacturing capability and regulatory documentation (DMF, CEP status) are what a formulator actually evaluates first — a homepage built around brand story rather than that documentation loses qualified buyers early.
A formulator qualifying a new API supplier needs to locate a specific filing quickly, and a site that buries documentation loses the enquiry regardless of how strong the underlying capability is. A layout template built for a different subsector was never asked to account for that.
A documentation-first architecture putting DMF and CEP status ahead of brand content, a component system built for technical evaluation, and an audit of where capability evidence is currently buried too deep to be found.
A formulator shortlisting suppliers checks DMF and CEP status before anything else — burying that documentation three levels deep in a generic “about us” structure is the single most common reason a technically qualified supplier gets dropped from a shortlist.
Active ingredient buyers evaluate at substance level: specification, pharmacopoeial compliance, impurity profile, polymorphic form, particle size, filing status by region. That information already exists in your regulatory documentation, and the useful website is largely a matter of exposing it as a page per molecule rather than as a portfolio list with an enquiry form. Generating those pages from the regulatory record keeps them accurate as filings progress, and it means a new certificate of suitability updates the site as a consequence of the regulatory work rather than as a separate marketing task that gets deferred.
The action that matters on an active ingredient site is not a contact form. It is a request for a specification sheet, a sample, an open part of a drug master file or a quality agreement — each requiring a different level of formality and sometimes a confidentiality agreement first. Building that as a considered document request flow, with clear expectations about what is provided immediately and what requires an agreement, converts far better than a generic enquiry box and gives your commercial team a qualified request rather than a name and a sentence.
What comes up when scoping a site for this category.
A formulator or procurement specialist partway through qualifying a new supplier, checking a specific active ingredient against a shortlist compiled from regulatory filings and existing relationships. They search narrowly — a CEP number, a DMF reference, a specific pharmacopoeia grade — and expect to locate that documentation directly rather than browse a general capabilities overview first.
Documentation should be organised by molecule and grade, with CEP and DMF references, analytical certificates, and regulatory status listed directly on each product page rather than buried in a general downloads library. A qualification reviewer needs to confirm filing status for a specific active ingredient within minutes, and a site that requires a sales enquiry to access that detail loses the enquiry to a competitor.
Yes. Beyond the site, we build and maintain the technical data sheets, regulatory filing summaries, and certificate libraries that a qualification process draws on. Keeping that documentation current as filings are renewed or grades are added matters as much as the initial build, since outdated status information can disqualify a supplier from a shortlist. See API Manufacturers for the full range.
Where order volume justifies it, yes — a lightweight account area lets existing customers check order status, reorder previous grades, and retrieve certificates of analysis without repeating a sales enquiry each time. It sits alongside the public-facing site rather than replacing it, since new prospects still need the open qualification documentation before becoming an account holder.
The open part is intended to be shareable and generally can be, along with the specification, pharmacopoeial reference and filing status. The restricted part stays behind an agreement, as it should. Where suppliers lose enquiries is by gating everything, including information a customer could obtain from a public register, which signals difficulty before any relationship exists. Making the open material genuinely accessible and being explicit about what requires an agreement is both safer and more commercially effective.
A template that was never built for a formulator mid-way through technical due diligence specifically. Tell us what you have and we will tell you what a structural fix would look like. Tell us your situation and we will tell you what a rebuild for a formulator mid-way through technical due diligence would actually change.